Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Cutia Therapeutics ( (HK:2487) ) is now available.
Cutia Therapeutics has reported a significant increase in revenue for the year ended December 31, 2024, with a 103% rise compared to the previous year, reaching approximately RMB280 million. The company has achieved effective cost control, with reductions in selling, distribution, R&D, and administrative expenses. The company’s commercialization efforts have been successful, particularly in the sales of scalp and skincare products, with notable growth during major sales campaigns. Additionally, Cutia has made progress in its product pipeline, with marketing approvals and clinical trials for several products, including CU-10201 for acne vulgaris and CU-40102 for androgenetic alopecia. The company has also expanded its manufacturing capabilities with a new facility in Wuxi.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands with a focus on developing and commercializing dermatological products. The company is involved in the pharmaceutical industry, primarily dealing with scalp diseases, skincare products, and other dermatological treatments.
YTD Price Performance: -16.67%
Average Trading Volume: 12,343,997
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.89B
For detailed information about 2487 stock, go to TipRanks’ Stock Analysis page.